JP2006514923A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514923A5
JP2006514923A5 JP2004546264A JP2004546264A JP2006514923A5 JP 2006514923 A5 JP2006514923 A5 JP 2006514923A5 JP 2004546264 A JP2004546264 A JP 2004546264A JP 2004546264 A JP2004546264 A JP 2004546264A JP 2006514923 A5 JP2006514923 A5 JP 2006514923A5
Authority
JP
Japan
Prior art keywords
depot preparation
preparation according
injectable depot
ziprasidone
sbecd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2004546264A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514923A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/004576 external-priority patent/WO2004037289A2/en
Publication of JP2006514923A publication Critical patent/JP2006514923A/ja
Publication of JP2006514923A5 publication Critical patent/JP2006514923A5/ja
Abandoned legal-status Critical Current

Links

JP2004546264A 2002-10-25 2003-10-13 注射可能な新規なデポ製剤 Abandoned JP2006514923A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42147302P 2002-10-25 2002-10-25
PCT/IB2003/004576 WO2004037289A2 (en) 2002-10-25 2003-10-13 Novel injectable depot formulations

Publications (2)

Publication Number Publication Date
JP2006514923A JP2006514923A (ja) 2006-05-18
JP2006514923A5 true JP2006514923A5 (enExample) 2006-11-24

Family

ID=32176718

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004546264A Abandoned JP2006514923A (ja) 2002-10-25 2003-10-13 注射可能な新規なデポ製剤

Country Status (20)

Country Link
US (1) US20040138237A1 (enExample)
EP (1) EP1575616A2 (enExample)
JP (1) JP2006514923A (enExample)
KR (1) KR20050055781A (enExample)
CN (1) CN1849110A (enExample)
AR (1) AR041722A1 (enExample)
AU (1) AU2003267788A1 (enExample)
BR (1) BR0315568A (enExample)
CA (1) CA2503076A1 (enExample)
MX (1) MXPA05002561A (enExample)
NL (1) NL1024590C2 (enExample)
NO (1) NO20052463L (enExample)
PA (1) PA8586201A1 (enExample)
PE (1) PE20040499A1 (enExample)
PL (1) PL377679A1 (enExample)
RU (1) RU2310450C2 (enExample)
TW (1) TW200423941A (enExample)
UY (1) UY28038A1 (enExample)
WO (1) WO2004037289A2 (enExample)
ZA (1) ZA200501921B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
EP2218448B1 (en) 2002-12-13 2015-09-23 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
KR20060115350A (ko) * 2003-09-02 2006-11-08 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
DK2767292T3 (en) 2004-09-17 2016-12-19 Durect Corp RENEWABLE local anesthetic COMPOSITION CONTAINING SAIB
EP1855651A4 (en) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd NANOPARTICLE COMPOSITIONS OF HETEROCYCLIC AMID DERIVATIVES
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
CA2603189A1 (en) * 2005-04-13 2006-10-19 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
CA2605153A1 (en) * 2005-04-13 2006-10-19 Jaymin Chandrakant Shah Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
KR20080024206A (ko) * 2005-06-20 2008-03-17 엘란 파마 인터내셔널 리미티드 아릴-헤테로시클릭 화합물을 함유하는 나노입자형 조절방출 조성물
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
KR100908517B1 (ko) * 2006-07-04 2009-07-20 (주)아모레퍼시픽 호흡기계 약제 전달을 위한 서방형 다공성 미세입자 및 그제조 방법
AU2007325918B2 (en) 2006-11-03 2013-10-17 Durect Corporation Transdermal delivery systems comprising bupivacaine
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
EP2067471B1 (en) * 2007-12-06 2018-02-14 Durect Corporation Oral pharmaceutical dosage forms
EP2303229A1 (en) * 2008-06-16 2011-04-06 Debiopharm S.A. Concentrated oxaliplatin solution and its method of preparation
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CN104688686A (zh) * 2015-02-10 2015-06-10 万全万特制药江苏有限公司 一种含有齐拉西酮及其盐的脂肪乳注射剂
CN109475505A (zh) 2016-07-06 2019-03-15 度瑞公司 具有药物组成物、屏障层及药物层的口服剂型
WO2018015915A1 (en) * 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
FR3087107A1 (fr) 2018-10-15 2020-04-17 Avent Inc. Compositions, systèmes, kits et méthodes d'ablation neurale
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029782A (en) * 1975-04-28 1977-06-14 Eli Lilly And Company Cefazolin suspension for parenteral administration
US4512986A (en) * 1983-07-26 1985-04-23 Research Triangle Institute Progrestationally active steroids
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
ATE318580T1 (de) * 1996-12-20 2006-03-15 Alza Corp Gelzusammensetzungen und verfahren
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
AU765603C (en) * 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
IL145950A0 (en) * 1999-05-27 2002-07-25 Pfizer Prod Inc Ziprasidone suspension
US6753011B2 (en) * 2000-01-14 2004-06-22 Osmotica Corp Combined diffusion/osmotic pumping drug delivery system
EP1383445A4 (en) * 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers

Similar Documents

Publication Publication Date Title
JP2006514923A (ja) 注射可能な新規なデポ製剤
EP1312356B1 (en) Aqueous suspension preparations
JP2005514349A5 (enExample)
US5773608A (en) Process for preparing stabilized chitin derivative compounds
US20090047330A1 (en) Oral fast dissolving films for erectile dysfunction bioactive agents
JP2007500244A5 (enExample)
EP2106787A3 (en) Biodegradable block copolymeric compositions for drug delivery
RU2005112202A (ru) Депо-препараты арилгетероциклических активных веществ в виде суспензии
JP2004510807A5 (enExample)
JP2006528990A5 (enExample)
JP2003512341A5 (enExample)
DK1968638T3 (en) Controlled release gels
CN100438871C (zh) 法莫替丁注射液
US20100267817A1 (en) Lyophilized pharmaceutical composition with improved reconstitution time containing taxane derivatives and method of manufacturing the same
CN100444828C (zh) 一种生物降解聚合物药物微球的制备方法
KR102421758B1 (ko) 안과용 조성물
JPH092977A (ja) 経口投与用医薬組成物
JP2004149468A (ja) 皮膚外用剤組成物
JPH1192368A (ja) ベンゾピラン誘導体を主成分とする水性液剤
JP2005527615A (ja) ナトリウムチャンネルブロッカーの非経口適用のための新規な製剤
王雅琪 et al. The effects of characteristics of chitosan on the heparin loaded chitosan microspheres
JP2003113121A (ja) 歯周病治療用組成物